315 results on '"Stuhler, Gernot"'
Search Results
2. Bispecific and multispecific antibodies in oncology: opportunities and challenges
3. Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)
4. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
5. Variant signaling topology at the cancer cell–T-cell interface induced by a two-component T-cell engager
6. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
7. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia—Lessons Learned from the Prospective BRIDGE Trial
8. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
9. On-target restoration of a split T cell-engaging antibody for precision immunotherapy
10. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation
11. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
12. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation
13. Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
14. Antigen Organization Regulates Cluster Formation and Induction of Cytotoxic T Lymphocytes by Helper T Cell Subsets
15. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
16. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
17. Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
18. Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)
19. Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial
20. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts
21. Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation
22. Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment
23. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update
24. Prevention of major infectious complications by pre-emptive enterostomy in patients awaiting allogeneic stem cell transplantation
25. Variant signaling topology at the cancer cell–T-cell interface induced by a two-component T-cell engager
26. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
27. Novel On-Target Restoration of a Split T Cell-Engaging Antibody for Precision Immunotherapy of Multiple Myeloma
28. Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors
29. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes
30. 94 - Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial
31. 42 - Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)
32. Transplant-related prediction of survival in primary myelofibrosis : a study by the EBMT
33. Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassified : A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
34. Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens
35. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
36. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation
37. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT
38. Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
39. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate or High-Risk Acute Myeloid Leukemia in Complete Remission: a Study From the ALWP of the EBMT
40. P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An “unconventional alliance” associated with a decreased relapse incidence in unrelated hematopoietic stem cell transplantation (UHSCT)
41. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT
42. Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study
43. Long Term Follow up and Impact of Comorbidity Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML - Lessons Learned from the Prospective Bridge Trial -
44. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT
45. Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT
46. Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT
47. Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality
48. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal
49. Anti‐CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.
50. Allogeneic Stem Cell Transplantation for t(3;3)(q21;q26)/Inv(3)(q21;q26) Acute Myeloid Leukemia – Report from the Acute Leukemia Working Party of the EBMT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.